ONCOLYTICS BIOTECH INC (ONC.CA) Stock Price, Forecast & Analysis
TSX:ONC • CA6823108759
ONC.CA Key Statistics, Chart & Performance
The current stock price of ONC.CA is 1.42 CAD. In the past month the price decreased by -7.19%. In the past year, price increased by 5.97%.
ONC.CA Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to ONC.CA. When comparing the yearly performance of all stocks, ONC.CA is one of the better performing stocks in the market, outperforming 91.32% of all stocks.
ONC.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ONC.CA. The financial health of ONC.CA is average, but there are quite some concerns on its profitability.
ONC.CA Financial Highlights
Over the last trailing twelve months ONC.CA reported a non-GAAP Earnings per Share(EPS) of -0.37. The EPS increased by 2.63% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -152.26% | ||
| ROE | -499.46% | ||
| Debt/Equity | 0.1 |
ONC.CA Forecast & Estimates
8 analysts have analysed ONC.CA and the average price target is 4.6 CAD. This implies a price increase of 224.02% is expected in the next year compared to the current price of 1.42.
ONC.CA Ownership
ONC.CA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| EPRX | EUPRAXIA PHARMACEUTICALS INC | N/A | 580.689M | ||
| EDT | SPECTRAL MEDICAL INC | N/A | 400.807M | ||
| HBP | HELIX BIOPHARMA CORP | N/A | 152.76M | ||
| MDNA | MEDICENNA THERAPEUTICS CORP | N/A | 71.733M | ||
| COV | COVALON TECHNOLOGIES LTD | 13.03 | 44.192M | ||
| BCT | BRIACELL THERAPEUTICS CORP | N/A | 40.89M | ||
| MBX | MICROBIX BIOSYSTEMS INC | 5.69 | 33.252M | ||
| RVX | RESVERLOGIX CORP | N/A | 28.756M | ||
| HEM | HEMOSTEMIX INC | N/A | 16.596M | ||
| MPH | MEDICURE INC | N/A | 11.693M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Toronto Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
About ONC.CA
Company Profile
Oncolytics Biotech, Inc. engages in the provision of development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The company is headquartered in Calgary, Alberta. The company went IPO on 2000-06-01. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The company acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype, turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. The firm is also advancing its programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/ HER2-) advanced and metastatic breast cancer (mBC) and metastatic pancreatic ductal adenocarcinoma (PDAC) to registration-enabled clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
Company Info
ONCOLYTICS BIOTECH INC
804, 322 - 11 Avenue Sw, Calgary Alberta Canada T2n 1X7
Calgary ALBERTA T2N 1X7 CA
CEO: Matthew C. Coffey
Employees: 28
Phone: 14036707377
ONCOLYTICS BIOTECH INC / ONC.CA FAQ
What does ONCOLYTICS BIOTECH INC do?
Oncolytics Biotech, Inc. engages in the provision of development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The company is headquartered in Calgary, Alberta. The company went IPO on 2000-06-01. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The company acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype, turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. The firm is also advancing its programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/ HER2-) advanced and metastatic breast cancer (mBC) and metastatic pancreatic ductal adenocarcinoma (PDAC) to registration-enabled clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
What is the current price of ONC stock?
The current stock price of ONC.CA is 1.42 CAD. The price increased by 2.16% in the last trading session.
Does ONCOLYTICS BIOTECH INC pay dividends?
ONC.CA does not pay a dividend.
How is the ChartMill rating for ONCOLYTICS BIOTECH INC?
ONC.CA has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the employee count for ONC stock?
ONCOLYTICS BIOTECH INC (ONC.CA) currently has 28 employees.
What is the market capitalization of ONC stock?
ONCOLYTICS BIOTECH INC (ONC.CA) has a market capitalization of 126.12M CAD. This makes ONC.CA a Micro Cap stock.
When does ONCOLYTICS BIOTECH INC (ONC.CA) report earnings?
ONCOLYTICS BIOTECH INC (ONC.CA) will report earnings on 2025-11-10, after the market close.